Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q8NEX9 (
reductase
)
26,410
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The primary sequences of the three mammalian nitric- oxide synthase (NOS) isoforms differ by the insertion of a 52-55-amino acid loop into the
reductase
domains of the endothelial (
eNOS
) and neuronal (nNOS), but not inducible (iNOS). On the basis of studies of peptide derivatives as inhibitors of.NO formation and calmodulin (CaM) binding (Salerno, J. C., Harris, D. E., Irizarry, K., Patel, B., Morales, A. J., Smith, S. M., Martasek, P., Roman, L. J., Masters, B. S., Jones, C. L., Weissman, B. A., Lane, P., Liu, Q., and Gross, S. S. (1997) J. Biol. Chem. 272, 29769-29777), the insert has been proposed to be an autoinhibitory element. We have examined the role of the insert in its native protein context by deleting the insert from both wild-type
eNOS
and from chimeras obtained by swapping the
reductase
domains of the three NOS isoforms. The Ca2+ concentrations required to activate the enzymes decrease significantly when the insert is deleted, consistent with suppression of autoinhibition. Furthermore, removal of the insert greatly enhances the maximal activity of wild-type
eNOS
, the least active of the three isoforms. Despite the correlation between
reductase
and overall enzymatic activity for the wild-type and chimeric NOS proteins, the loop-free
eNOS
still requires CaM to synthesize.NO. However, the reductive activity of the CaM-free, loop-deleted
eNOS
is enhanced significantly over that of CaM-free wild-type
eNOS
and approaches the same level as that of CaM-bound wild-type
eNOS
. Thus, the inhibitory effect of the loop on both the
eNOS
reductase
and. NO-synthesizing activities may have an origin distinct from the loop's inhibitory effects on the binding of CaM and the concomitant activation of the
reductase
and.NO-synthesizing activities. The
eNOS
insert not only inhibits activation of the enzyme by CaM but also contributes to the relatively low overall activity of this NOS isoform.
...
PMID:Autoinhibition of endothelial nitric-oxide synthase. Identification of an electron transfer control element. 1032 64
The Ca(2+)-calmodulin system controls the neuronal and endothelial isoforms of NOS, whereas the inducible isoform is calcium independent apparently because CaM is a tightly bound subunit of iNOS. The canonical CaM-binding site is located between the oxygenase and
reductase
NOS domains. CaM controls
eNOS
dimerization rather then iNOS one. The proteins with the so-called "IQ" motif bind calmodulin in a Ca(2+)-independent manner. This group of proteins does not include iNOS, which has the canonical CaM-binding motif. In the experiments with synthetic peptides was demonstrated that the interaction between the calmodulin and CaM-binding site of iNOS does not depend on the Ca2+ concentration. On the other hand, in the experiments with fusion, mutant and truncated NOSs was shown that these features of CaM-binding region of iNOS is not enough for the enzyme to bind calmodulin Ca(2+)-independently; this interaction requires the additional binding sites both in
reductase
and oxygenase domains of iNOS. In the experiments with fusion calmodulins the mechanism of calmodulin regulation of electron transfer in NOS was elaborated. The concept of autoinhibitory control element in the FMN-binding site of constitutive NOS is discussed.
...
PMID:[Mechanisms of regulation by calmodulin of nitric oxide synthase]. 1043 53
To clarify the role of the autoinhibitory insert in the endothelial (
eNOS
) and neuronal (nNOS) nitric-oxide synthases, the insert was excised from nNOS and chimeras with its
reductase
domain; the
eNOS
and nNOS inserts were swapped and put into the normally insertless inducible (iNOS) isoform and chimeras with the iNOS
reductase
domain; and an RRKRK sequence in the insert suggested by earlier peptide studies to be important (Salerno, J. C., Harris, D. E., Irizarry, K., Patel, B., Morales, A. J., Smith, S. M., Martasek, P., Roman, L. J., Masters, B. S., Jones, C. L., Weissman, B. A., Lane, P., Liu, Q., and Gross, S. S. (1997) J. Biol. Chem. 272, 29769-29777) was mutated. Insertless nNOS required calmodulin (CaM) for normal NOS activity, but the Ca(2+) requirement for this activity was relaxed. Furthermore, insert deletion enhanced CaM-free electron transfer within nNOS and chimeras with the nNOS
reductase
, emphasizing the involvement of the insert in modulating electron transfer. Swapping the nNOS and
eNOS
inserts gave proteins with normal NOS activities, and the nNOS insert acted normally in raising the Ca(2+) dependence when placed in
eNOS
. Insertion of the
eNOS
insert into iNOS and chimeras with the iNOS
reductase
domain significantly lowered NOS activity, consistent with inhibition of electron transfer by the insert. Mutation of the
eNOS
RRKRK to an AAAAA sequence did not alter the
eNOS
Ca(2+) dependence but marginally inhibited electron transfer. The salt dependence suggests that the insert modulates electron transfer within the
reductase
domain prior to the heme/
reductase
interface. The results clarify the role of the
reductase
insert in modulating the Ca(2+) requirement, electron transfer rate, and overall activity of nNOS and
eNOS
.
...
PMID:Control of electron transfer in nitric-oxide synthases. Swapping of autoinhibitory elements among nitric-oxide synthase isoforms. 1126 92
Neuronal nitric-oxide synthase (nNOS or NOS I) and endothelial NOS (
eNOS
or NOS III) differ widely in their
reductase
and nitric oxide (NO) synthesis activities, electron transfer rates, and propensities to form a heme-NO complex during catalysis. We generated chimeras by swapping
eNOS
and nNOS oxygenase domains to understand the basis for these differences and to identify structural elements that determine their catalytic behaviors. Swapping oxygenase domains did not alter domain-specific catalytic functions (cytochrome c reduction or H(2)O(2)-supported N(omega)-hydroxy-l-arginine oxidation) but markedly affected steady-state NO synthesis and NADPH oxidation compared with native
eNOS
and nNOS. Stopped-flow analysis showed that
reductase
domains either maintained (nNOS) or slightly exceeded (
eNOS
) their native rates of heme reduction in each chimera. Heme reduction rates were found to correlate with the initial rates of NADPH oxidation and heme-NO complex formation, with the percentage of heme-NO complex attained during the steady state, and with NO synthesis activity. Oxygenase domain identity influenced these parameters to a lesser degree. We conclude: 1) Heme reduction rates in nNOS and
eNOS
are controlled primarily by their
reductase
domains and are almost independent of oxygenase domain identity. 2) Heme reduction rate is the dominant parameter controlling the kinetics and extent of heme-NO complex formation in both
eNOS
and nNOS, and thus it determines to what degree heme-NO complex formation influences their steady-state NO synthesis, whereas oxygenase domains provide minor but important influences. 3) General principles that relate heme reduction rate, heme-NO complex formation, and NO synthesis are not specific for nNOS but apply to
eNOS
as well.
...
PMID:Chimeras of nitric-oxide synthase types I and III establish fundamental correlates between heme reduction, heme-NO complex formation, and catalytic activity. 1131 63
Recent studies have reported that hydroxymethylglutaryl coenzyme A (HMG-CoA)
reductase
inhibitors have vasculoprotective effects independent of their lipid-lowering properties, including anti-inflammatory actions. We used intravital microscopy of the rat mesenteric microvasculature to examine the effects of rosuvastatin, a new HMG-CoA reductase inhibitor, on leukocyte-endothelium interactions induced by thrombin. Intraperitoneal administration of 0.5 and 1.25 mg kg(-1) rosuvastatin 18 h prior to the study, significantly and dose-dependently attenuated leukocyte rolling, adherence, and transmigration in the rat mesenteric microvasculature superfused with 0.5 u ml(-1) thrombin. This protective effect of rosuvastatin was reversed by intraperitoneal injection of 25 mg kg(-1) mevalonic acid 18 h before the study. Immunohistochemical detection of the endothelial cell adhesion molecule P-selectin showed a 70% decrease in endothelial cell surface expression of P-selectin in thrombin-stimulated rats given 1.25 mg kg(-1) rosuvastatin. In addition, rosuvastatin enhanced release of nitric oxide (NO) from the vascular endothelium as measured directly in rat aortic segments. Moreover, rosuvastatin failed to attenuate leukocyte-endothelium interactions in peri-intestinal venules of
eNOS
(-/-) mice. These data indicate that rosuvastatin exerts important anti-inflammatory effects via inhibition of endothelial cell adhesion molecule expression, and that this protective action of rosuvastatin requires release of nitric oxide by the vascular endothelium. These data also demonstrate that the mechanism of the non-lipid lowering actions of HMG-CoA reductase inhibitors in vivo may be due to reduced formation or availability of mevalonic acid within endothelial cells.
...
PMID:A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. 1137 57
Dementia in Alzheimer's disease (AD) is correlated with cell loss that is mediated by apoptosis, mitochondrial (Mt) dysfunction, and possibly necrosis. Previous studies demonstrated increased expression of the
nitric oxide synthase 3
(
NOS3
) gene in degenerating neurons of AD brains. For investigating the role of
NOS3
overexpression as a mediator of neuronal loss, human PNET2 central nervous system-derived neuronal cells were infected with recombinant adenovirus vectors that expressed either human
NOS3
or green fluorescent protein cDNA under the control of a CMV promoter.
NOS3
overexpression resulted in apoptosis accompanied by increased levels of p53, p21/Waf1, Bax, and CD95. In addition,
NOS3
overexpression impaired neuronal Mt function as demonstrated by the reduced levels of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide and nicotinamide adenine dinucleotide (reduced form)-tetrazolium
reductase
activities and MitoTracker Red fluorescence. These adverse effects of
NOS3
were associated with increased cellular levels of reactive oxygen species and impaired membrane integrity and were not produced in cells that were transfected with a cDNA encoding catalytically inactive
NOS3
. Importantly, modest elevations in
NOS3
expression, achieved by infection with low multiplicities of adenovirus-
NOS3
infection, did not cause apoptosis but rendered the cells more sensitive to oxidative injury by H(2)O(2) or diethyldithiocarbamate. In contrast, treatment with NO donors did not enhance neuronal sensitivity to oxidative injury. These results suggest that
NOS3
-induced neuronal death is mediated by Mt dysfunction, oxidative injury, and impaired membrane integrity, rather than by NO production, and that neuroprotection from these adverse effects of
NOS3
may be achieved by modulating intracellular levels of oxidative stress.
...
PMID:Nitric oxide synthase-3 overexpression causes apoptosis and impairs neuronal mitochondrial function: relevance to Alzheimer's-type neurodegeneration. 1259 42
Oxygenase and
reductase
domains in nitric oxide synthase are linked by a peptide region that binds calmodulin. Here we study the effects of modifying the length of the interdomain linker in a deletion mutant lacking 15 amino acids (residues 503-517) in bovine
eNOS
. The kinetics of CO ligation with the mutant were determined in the presence and absence of tetrahydrobiopterin and arginine and compared with the CO binding kinetics of wild-type
eNOS
and the
eNOS
oxygenase domain. In the mutant, electron flow is interrupted. The association kinetics of CO with both mutant and wild-type
eNOS
can be approximated with two kinetic phases, but the relative proportions change in the mutant. Both the abrogation of electron flow in the mutant and the differences in CO binding may be explained by an alteration in the docking of the FMN domain to the heme domain. We propose that the calmodulin binding residues form a helix that is critical for the proper alignment of the adjacent
reductase
and oxygenase domains within the active
eNOS
dimer in achieving proper electron transfer between them.
...
PMID:Role of the interdomain linker probed by kinetics of CO ligation to an endothelial nitric oxide synthase mutant lacking the calmodulin binding peptide (residues 503-517 in bovine). 1276 33
Inducible (iNOS) and constitutive (
eNOS
, nNOS) nitric-oxide synthases differ in their Ca2+-calmodulin (CaM) dependence. iNOS binds CaM irreversibly but
eNOS
and nNOS, which bind CaM reversibly, have inserts in their
reductase
domains that regulate electron transfer. These include the 43-45-amino acid autoinhibitory element (AI) that attenuates electron transfer in the absence of CaM, and the C-terminal 20-40-amino acid tail that attenuates electron transfer in a CaM-independent manner. We constructed models of the
reductase
domains of the three NOS isoforms to predict the structural basis for CaM-dependent regulation. We have identified and characterized a loop (CD2A) within the NOS connecting domain that is highly conserved by isoform and that, like the AI element, is within direct interaction distance of the CaM binding region. The
eNOS
CD2A loop (eCD2A) has the sequence 834KGSPGGPPPG843, and is truncated to 809ESGSY813 (iCD2A) in iNOS. The eCD2A contributes to the Ca2+ dependence of CaM-bound activity to a level similar to that of the AI element. The eCD2A plays an autoinhibitory role in the control of NO, and CaM-dependent and -independent
reductase
activity, but this autoinhibitory function is masked by the dominant AI element. Finally, the iCD2A is involved in determining the salt dependence of NO activity at a post-flavin reduction level. Electrostatic interactions between the CD2A loop and the CaM-binding region, and CaM itself, provide a structural means for the CD2A to mediate CaM regulation of intra-subunit electron transfer within the active NOS complex.
...
PMID:Nitric-oxide synthase (NOS) reductase domain models suggest a new control element in endothelial NOS that attenuates calmodulin-dependent activity. 1280 87
Several calmodulin (CaM) mutants were engineered in an effort to identify the functional implications of the oxidation of individual methionines in CaM on the activity of the constitutive isoforms of nitric oxide synthase (NOS). Site-directed mutagenesis was used to substitute the majority of methionines with leucines. Substitution of all nine methionine residues in CaM with leucines had minimal effects on the binding affinity or maximal enzyme activation for either the neuronal (nNOS) or endothelial (
eNOS
) isoform. Selective substitution permitted determination of the functional consequences of the site-specific oxidation of Met(144) and Met(145) on the regulation of electron transfer within nNOS and
eNOS
. Site-specific oxidation of Met(144) and Met(145) resulted in changes in the CaM concentration necessary for half-maximal activation of nNOS and
eNOS
, suggesting that these side chains are involved in stabilizing the productive association between CaM and NOS. However, the site-specific oxidation of Met(144) and Met(145) had essentially no effect on the maximal extent of
eNOS
activation in the presence of saturating concentrations of CaM. In contrast, the site-specific oxidation of Met(144) (but not Met(145)) resulted in a reduction in the level of nNOS activation that was associated with decreased rates of electron transfer within the
reductase
domain. Thus, nNOS and
eNOS
exhibit different functional sensitivities to conditions of oxidative stress that are expected to oxidize CaM. This may underlie some aspects of the observed differences in the sensitivities of proteins in vasculature and neuronal tissues to nitration that are linked to NOS activation and the associated generation of peroxynitrite.
...
PMID:Activation of constitutive nitric oxide synthases by oxidized calmodulin mutants. 1282 Aug 85
Catalytic activity of
eNOS
is regulated by multiple posttranscriptional mechanisms, including a 40-amino acid (604-643) autoinhibitory domain (AID) located in the
reductase
domain of the
eNOS
protein. We examined whether an exogenous synthetic AID, an 11-amino acid (626-636) fragment of AID (AAF), or scrambled AAF (AAF-SR), enhanced
eNOS
activity and NO-cGMP-mediated vasorelaxation using pulmonary artery (PA) endothelial/smooth muscle cell (PAEC/PASM) coculture, isolated PA segment, and isolated lung perfusion models. Incubation of isolated total membrane fraction of PAEC with AID or AAF resulted in concentration-dependent loss of
eNOS
activity. In contrast, incubation of intact PAEC with AID or AAF but not AAF-SR caused concentration- and time-dependent activation of
eNOS
. Because AID and AAF had similar effects on activation of
eNOS
, AAF and AAF-SR were used for further evaluation. Although AAF stimulation increased catalytic activity of PKC-alpha in PAEC, AAF-mediated activation of
eNOS
was independent of phosphorylation of Ser1177 or Thr495 and/or expression of
eNOS
protein. AAF stimulation of PAEC increased NO and cGMP production, which were attenuated by pretreatment with the
eNOS
inhibitor l-NAME. AAF caused time-dependent vasodilation of U-46619-precontracted endothelium-intact but not endothelium-denuded PA segments, and this response was attenuated by l-NAME. AAF, but not AAF-SR, also caused vasorelaxation in an ex vivo isolated mouse lung perfusion model precontracted with U-46619. Incubation with fluorescence-labeled AAF demonstrated translocation of AAF in PAEC in culture, isolated PA, and isolated intact lungs. These results demonstrate that AAF-stimulated vasodilation is mediated via activation of
eNOS
and enhanced NO-cGMP production in PA and intact lung.
...
PMID:Autoinhibitory domain fragment of endothelial NOS enhances pulmonary artery vasorelaxation by the NO-cGMP pathway. 1472 13
1
2
3
4
5
Next >>